About Relitect
Relitect is a company based in Lanark (United Kingdom) founded in 2014. Relitect has raised $1.13 million across 1 funding round from investors including Scottish Enterprise and IP Group. Relitect operates in a competitive market with competitors including Quiver Bioscience, MaxWell Biosystems, Forcyte Biotechnologies, Novoheart and Multi Channel Systems, among others.
- Headquarter Lanark, United Kingdom
- SectorsHealthcare
- Email••••••••
- Website relitect.com
- Social LinkedIn X
- Total Equity Funding$1.13M (USD)
in 1 rounds
- Latest Funding Round$1.13M (USD), Seed
Mar 2015
- InvestorsScottish Enterprise
& 1 more
Funding Insights of Relitect
Relitect has successfully raised a total of $1.13M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.13 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.13M
- Total Rounds 1
- Last Round Seed — $1.13M
- First Round $1.13M
(Mar 2015)
- Investors Count 2
All 1 funding rounds of Relitect with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2015 | $1.13M | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Relitect
Relitect has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Scottish Enterprise and IP Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and advisory services are offered across multiple sectors. | 2001 | ipgroupplc.com | London, United Kingdom | |
Business development and leadership training programs are offered to companies. | 1991 | scottish-enterprise.com | Glasgow, United Kingdom |
Investor details for Relitect
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Relitect
2 dated milestones of Relitect across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Relitect is founded.
- Funding First funding round of $1.1M.
Competitors of Relitect
Relitect operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Quiver Bioscience, MaxWell Biosystems, Forcyte Biotechnologies, Novoheart and Multi Channel Systems, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| quiverbioscience.com | 2013 | Cambridge, United States | – | – | Developer of transformational medicines for neurological disorders | |
| mxwbio.com | 2016 | Basel, Switzerland | $4.64M | – | In vitro electrophysiology platform for electrogenic cell analysis is developed. | |
| forcytebio.com | 2017 | Los Angeles, United States | $1.13M | – | Automated single-cell contractility screening systems are developed for drug discovery. | |
| novoheart.com | 2014 | Vancouver, Canada | – | – | Bioartificial hearts are engineered using stem cells and tissue methods. | |
| multichannelsystems.com | 1996 | Reutlingen, Germany | – | 68 | Tools and systems for electrophysiology are developed and supplied. | |
| sysmex-europe.com | 1980 | Norderstedt, Germany | – | – | Sysmex Europe offers diagnostic instruments and services for healthcare laboratories worldwide. | |
| cytocybernetics.com | 2013 | Buffalo, United States | – | – | Electrophysiology tools such as patch clamp systems are developed. | |
| nanion.de | 2002 | Munich, Germany | – | – | Automated patch clamp platforms for electrophysiology are developed. | |
| 3brain.com | 2011 | Wadenswil, Switzerland | – | – | High-resolution MEA platforms are supplied for electrophysiology research. |
Detailed competitors of Relitect
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Relitect
10 companies that operate in the same segment as Relitect (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Relitect
Relitect was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Relitect is headquartered in Lanark, United Kingdom. It is registered at Lanark, South Lanarkshire, United Kingdom.
Relitect is a funded company, having raised a total of $1.13M across 1 funding round to date. The company's 1st funding round was a Seed of $1.13M, raised on Mar 2015.
Relitect was founded in 2014 in Lanark, United Kingdom, within the biotechnology sector. Solutions for label-free detection of biomolecules are developed using a proprietary platform. An array of gold electrodes is coated with polymers conjugated to specific antibodies, targeting chosen biomarkers. Electrochemical impedance changes are measured when biomarkers bind to antibodies, facilitating sensor-based detection. Operations focus on advancing this technology for biomolecular analysis.
Relitect's top competitors include Quiver Bioscience, Novoheart and Forcyte Biotechnologies.
Relitect has 2 investors. Key investors include Scottish Enterprise, and IP Group.